Alvotech (ALVO) Q1 2025 Earnings Call Transcript
Alvotech (NASDAQ:ALVO ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Benedikt Stefansson - VP, Investor Relations and Global Communications Robert Wessman - Founder, Chairman and CEO Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Alvotech Q1 2025 Earnings Conference Call.
Alvotech (ALVO) Q4 2024 Earnings Call Transcript
Alvotech (NASDAQ:ALVO ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Robert Wessman - Chairman, Chief Executive Officer Anil Okay - Chief Commercial Officer Joseph McClellan - Chief Scientific Officer Joel Morales - Chief Financial Officer Benedikt Stefannson - Vice President, Investor Relations Conference Call Participants Ashwani Verma - UBS Operator Good day and thank you for standing by. Welcome to the Alvotech Q4 2024 earnings call.
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States.
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Teva Pharmaceutical Industries (TEVA) and partner Alvotech (ALVO) said the Food and Drug Administration (FDA) agreed to review their AVTO6 treatment for eye disorders.
Has Alvotech (ALVO) Outpaced Other Medical Stocks This Year?
Here is how Alvotech (ALVO) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
Here is how Alvotech (ALVO) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade
The mean of analysts' price targets for Alvotech (ALVO) points to a 39.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year?
Here is how Alvotech (ALVO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Alvotech's Position In The Coming Biosimilar Gold Rush
Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector.
Alvotech (ALVO) Q3 2024 Earnings Call Transcript
Alvotech (NASDAQ:ALVO ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director, Investor Relations and Global Communications Robert Wessman - Chairman and Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Ming Li - Chief Strategy Officer Conference Call Participants Balaji Prasad - Barclays Niall Alexander - Deutsche Bank Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Alvotech's Third Quarter 2024 Earnings Conference Call.
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates
Alvotech (ALVO) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to loss of $0.82 per share a year ago.
Alvotech (ALVO) Shares Up 3.77% on Oct 2
Shares of Alvotech (ALVO, Financial) surged 3.77% in mid-day trading on Oct 2. The stock reached an intraday high of $12.50, before settling at $12.40, up from its previous close of $11.95.
